PH-762 — FDA meeting
Q3 2026
Phio intends to request an FDA meeting in the third quarter of 2026 to discuss next steps in the clinical trial design and development strategy for PH-762.Source filing
PHIO biotech catalysts & pipeline
PHIO PHARMACEUTICALS CORP · Data as of 2026-09-08